BL
RARE icon

BFSG LLC’s Ultragenyx Pharmaceutical RARE Stock Holding History

BFSG LLC’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$8.41K – 701
2024
Q4 		$8.41K Hold
200
– – ﹤0.01% 515
2024
Q3 		$11.1K Hold
200
– – ﹤0.01% 488
2024
Q2 		$8.22K Hold
200
– – ﹤0.01% 497
2024
Q1 		$9.34K Hold
200
– – ﹤0.01% 503
2023
Q4 		$9.56K Buy
+200
New +$7.75K ﹤0.01% 459

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BFSG LLC's RARE Position: Q1 2025 in Review

BFSG LLC sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 200 shares — an estimated $8.41K sold.

BFSG LLC first reported a position in RARE in Q4 2023 and held it in 5 quarters. The position peaked at $11.1K in Q3 2024. 299 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

  • BFSG LLC reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • BFSG LLC sold 200 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $8.41K.
  • BFSG LLC first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 5 quarters.
  • BFSG LLC's Ultragenyx Pharmaceutical position peaked at $11.1K in Q3 2024.
  • 299 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on BFSG LLC's 13F filing for Q1 2025, filed 18 Apr 2025.